Insulet Corporation · NASDAQ:PODD
Insulet — Investor Presentation (January 2023)
19 slides from Insulet's investor presentation, January 2023
Slide 1: Insulet Corporation Investor Presentation
Insulet Corporation Investor Presentation January 2023 Christian D Podder since 2020 1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments a
Slide 3: Today's Agenda
Today’s Agenda 1 Capturing the Large and Underpenetrated Market 2 Realizing the Omnipod 5 Opportunity 3 Penetrating and Leading in the Type 2 Diabetes Market 4 Powering Mission with Strong Financial Profile Giuliana P Podder since 2016 3
Slide 4: Our Mission and How We Achieve It
Our Mission and How We Achieve It Simplify life for people with diabetes • Omnipod platform • Reduce burden • Improve outcomes Market-leading technology Market-leading revenue growth Competitive Advantages Long-term value creation • Talent • Innovation • Scalable Operations • Data infrastructure Jad
Slide 5: Delivering Results while Expanding our Portfolio
Delivering Results while Expanding our Portfolio 2022 Results Total estimated Omnipod growth of 23-24%1 510(k) submission for Basal-Only Pod Omnipod 5 Almost 75% U.S. pharmacy volume in Q3’221 U.S. commercial launch Increased TAM through global expansion Indication expanded down to age 2 CE mark app
Slide 6: Massive Market Opportunity
Massive Market Opportunity Current Total Addressable Market 537M+ People with Diabetes Worldwide1 ~11M People 2 ~64M ~40% ~60% Requiring Insulin Worldwide1 Type 1 Insulin-Intensive Type 2 2024 ~14M With U.S. Basal-Only Pod Morgan M Podder since 2009 1. Source: IDF Atlas 10th Edition. 2. Comprised of
Slide 7: Omnipod Is Unlocking the Largest Market Opportunity
Omnipod Is Unlocking the Largest Market Opportunity Conventional Insulin Pump Multiple Daily Injections (MDI) ~5% ~95% of the global market opportunity1 of the global market opportunity1 Alecia B Podder since 2017 vs. vs. One Pod replaces approximately 14 injections 7 1. Percentage of global insulin
Slide 8: Omnipod 5 Wins on All Dimensions
Omnipod 5 Wins on All Dimensions The Obvious OMNIPOD PLATFORM + OMNIPOD 5 WITH AID = Choice • No needles or tubes • Novel algorithm using micro-dose technology • Discreet, wearable, disposable • Industry-leading time in range • Pay-as-you-go economics for customers and payors • Very few hypoglycemic
Slide 9: Omnipod 5 Delivers Exciting Clinical Outcomes
Omnipod 5 Delivers Exciting Clinical Outcomes Time in TIR Time in Age Group range (TIR) improvement closed loop 14-70 yrs1 73.9% 9.3% 96.7% 6-13 yrs1 68.0% 15.6% 96.4% 2-5 yrs2 68.1% 10.9% 97.8% Strong performance in the pivotal trials 1. Brown SA, Forlenza GP, et al. Multicenter Trial of a Tubeless
Slide 10: Building a Full Range of Options for Type 2
Building a Full Range of Options for Type 2 Patient Journey Diet & Exercise Oral Medications Basal Insulins Basal-Bolus Insulins Omnipod DASH Improved glycemic management and reduction in insulin usage Basal-Only Pod No needles, ease of Omnipod 5 adoption and expected All the benefits of improved ad
Slide 11: Innovation Drives Horizons of Growth
Innovation Drives Horizons of Growth Value 537M+ People with Diabetes Worldwide1 Lead the Industry with ~64M Requiring Insulin Novel Innovations Worldwide1 Expand TAM • Next-generation algorithms Drive Omnipod 5 Growth • Next-generation hardware • AI / machine learning-based data • Basal-Only Pod an
Slide 12: Leveraging our Manufacturing Capabilities
Leveraging our Manufacturing Capabilities • Creating Supply Chain Redundancy – Regionally diverse manufacturing • Expanding Global Capacity – New Malaysia facility under construction • Building Talent and Capabilities – 20+ years of Pod engineering experience Insulet U.S. Manufacturing 12
Slide 13: Strong Financial Profile Powering the Mission
Strong Financial Profile Powering the Mission Maximizing Investing Expanding Revenue for Growth Operating Margins ~22% ~19% +~10pts Revenue CAGR R&D CAGR Adjusted Operating Margin 2017 - 20221 2017 - 20222 2017 - YTD Q3 20223 1. 2022 reported revenue estimate as provided on the Q3'22 earnings call o
Slide 14: Incredible 2022 ESG progress
Incredible 2022 ESG progress Launched Product Takeback pilot 67% of our current Board of in U.S. to explore shift to a more Directors are gender and/or circular business model ethnically diverse Received ‘AA’ MSCI Environmental, Social, and Governance (ESG) rating Generated 900+ MWh Obtained additio
Slide 15: Positioned for Continued Success
Positioned for Continued Success 1 Capturing the Large and Underpenetrated Market 2 Realizing the Omnipod 5 Opportunity 3 Penetrating and Leading in the Type 2 Diabetes Market 4 Powering Mission with Strong Financial Profile Ernesto M Podder since 2017 15
Slide 16: Thank You
Thank You Grant H Podder since 2022 16
Slide 17: Appendix
Appendix Insulet
Slide 18: Reconciliation of Non-GAAP Measures Revenue Guidance
Reconciliation of Non-GAAP Measures Revenue Guidance Year Ending December 31, 2022 Revenue Growth Revenue Growth Currency Impact GAAP Constant Currency U.S. Omnipod 30% to 31% —% 30% to 31% International Omnipod (1)% to —% (12)% 11% to 12% Total Omnipod 19% to 20% (4)% 23% to 24% Drug Delivery (37)%
Slide 19: Reconciliation of Non-GAAP Measures Operating Margin
Reconciliation of Non-GAAP Measures Operating Margin Nine Months Ended September 30, 2022 (dollars in millions) Operating Income Revenue Percent of Revenue GAAP $14.1 $935.6 1.5% Voluntary medical device correction1 36.8 Legal costs2 27.3 CEO transition costs3 3.4 Non-GAAP $81.6 $935.6 8.7% The Comp